Where does Bicara Therapeutics's income statement data come from?

Every line is extracted from Bicara Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Research and development	——	——	$112M+107%	$94.9M+110%	$85.9M—
General and administrative	$35.8M+56.4%	$30.51M+62.5%	$29.13M+92.4%	$26.19M+102%	$22.88M—
Compensation and benefits	——	——	——	——	——
Occupancy and equipment	——	——	——	——	——
Depreciation and amortization	——	——	——	——	——
Impairment charges	——	$0—	$0—	$0—	$0—
Other operating expenses	28,854,000,000%+12,398,500,000%	27,008,600,000%+13,194,500,000%	19,687,100,000%+10,123,000,000%	17,682,300,000%+9,228,000,000%	16,455,500,000%—
Total operating expenses	$174.06M+60.0%	$155.6M+88.9%	$141.12M+103%	$121.07M+108%	$108.8M—
Operating income	-$174.06M-60.0%	-$155.6M-88.9%	-$141.12M-103%	-$121.07M-108%	-$108.8M—
Interest income	$16.94M+1.3%	$17.87M+22.6%	$19.95M+99.2%	$18.71M+172%	$16.73M—
Other income (expense), net	$16.94M+1.3%	$17.87M+22.6%	$19.95M—	$18.71M—	$16.73M—
Income before income taxes	-$157.12M-70.6%	-$137.73M-103%	-$121.17M-104%	-$102.36M-57.9%	-$92.08M—
Income tax expense	$197K-23.6%	$217K+16.0%	$350K—	$310K—	$258K—
Net income	-$157.32M-70.4%	-$137.95M-103%	-$121.52M-104%	-$102.67M-58.3%	-$92.33M-61.8%
Diluted earnings per share	-$2.78—	-$2.53—	——	——	——
Basic earnings per share	-$2.78—	-$2.53—	——	——	——
Weighted-average shares, diluted	224.5M+170%	218.2M+646%	180.4M+1,283%	136.7M+4,899%	83.1M—
Weighted-average shares, basic	224.5M+170%	218.2M+646%	180.4M+1,283%	136.7M+4,899%	83.1M—
Accretion (Amortization) of Discounts and Premiums, Investments	——	——	——	——	——
Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment1	——	$0—	$0—	$0—	$0—
Share-based compensation expense related to employee stock plans	$17.41M+79.5%	$15.01M+103%	$13.74M—	$12.16M—	$9.7M—
Pre-tax stock-based compensation cost	$17.41M—	$15.01M—	$13.74M—	$12.16M—	——
Stock options excluded as their inclusion would be anti-dilutive (in shares)	——	——	——	——	——
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation	——	——	——	——	$166.81M—
Voting rights, votes per share	——	1—	——	——	——
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$157.56M—	-$137.71M—	-$121.66M—	-$102.67M—	——
Federal	——	$0—	$0—	$0—	$0—
Current State And Local Tax Expense Benefit	——	$217K+16.0%	$209.5K—	$202K—	$194.5K—
Federal	——	$0—	$0—	$0—	$0—
Deferred taxes	——	$0—	$0—	$0—	$0—
State	——	$0—	$0—	$0—	$0—
Defined Contribution Plan Cost Recognized	$500K—	$400K—	$400K—	$400K—	——
Depreciation	$130K+110%	$105K+87.5%	$77K+40.0%	$68K—	$62K—
Effective tax rates	——	-$0—	-$0—	-$0—	-$0—
Income taxes at U.S. statutory rate of 21%	——	——	——	——	——
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	——	——	——	——	——
Other	——	-$0—	——	——	——
Share-based compensation	——	——	——	——	——
Permanent differences	——	——	——	——	——
State income taxes – net of federal income tax benefit	——	——	——	——	——
Effective Income Tax Rate Reconciliation Tax Credits Research	——	——	——	——	——
Effective Income Tax Rate Reconciliation, Tax Credit, Percent	——	——	——	——	——
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	——	$31.49M—	——	——	——
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	——	-$28.92M—	——	——	——
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount	——	$59K—	——	——	——
Share-based compensation	——	$712K—	——	——	——
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount	——	$95K—	——	——	——
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount	——	$165K—	——	——	——
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	——	$3.38M—	——	——	——
Income taxes paid	——	——	——	——	——
Short- and long-term operating lease liabilities	-$1.06M-52,850%	-$932K-1,251%	-$348K-38.6%	-$103K—	$2K—
Increase (Decrease) in Prepaid Expense and Other Assets	-$3.56M-128%	-$5.58M-133%	$11.83M+2,842%	$11.94M—	$12.56M—
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	$195.15M-22.2%	$32.26M-90.3%	$84.54M-81.0%	$167.61M—	$250.98M—
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	-$217.51M—	-$318.45M—	-$236.16M—	——	——
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	-$116.24M-31.7%	-$106.83M-42.9%	-$112.98M-114%	-$100.96M—	-$88.27M—
Number of operating segments	1.8—	1—	——	——	——
Number of reportable segments	1.8—	1—	——	——	——
Offering costs included in accounts payable and accrued expenses	——	——	——	——	——
Occupancy and Related Charges	——	——	——	——	——
Operating lease right-of-use assets amortization expense	——	——	——	——	——
Non-cash lease expense	——	$895K+1,262%	$652K—	$409K—	$166K—
Net unrealized debt securities gains (losses), net of tax	-$243K—	$243K—	-$136K—	$0—	——
Unrealized gains (losses) on available-for-sale securities	——	——	——	——	——
Other comprehensive income/(loss)	-$243K—	$243K—	-$136K—	$0—	——
Payments to Acquire Property, Plant, and Equipment	$340K+407%	$280K+294%	$82K-82.4%	$48K—	$67K—
Proceeds From Issuance Initial Public Offering	——	——	——	——	——
Proceeds from Issuance of Common Stock	——	——	——	——	$249.32M—
Proceeds from disposition of marketable securities and other investments	——	——	——	——	——
Cash received from option exercises	$3.89M+102%	$2.76M+72.3%	$1.11M-29.2%	$732K-52.5%	$1.93M+675%
Stock-based compensation	$17.41M+79.5%	$15.01M+103%	$13.74M+176%	$12.16M—	$9.7M—
Weighted-average grant date fair value of stock options (in dollars per share)	——	——	——	——	——
Granted (in shares)	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period	——	——	——	——	——
Risk-free rate	——	——	——	——	——
Expected dividend rate	——	——	——	——	——
Weighted-average volatility	——	——	——	——	——
Intrinsic value of stock options exercised	——	——	——	——	$1.5M—
Options canceled (in dollars per share)	——	——	——	——	——
Granted (in shares)	——	——	——	——	——
Exercised (in shares)	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period	——	——	——	——	——
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment	$183.89M—	$29.5M—	——	——	——
Stock Issued During Period, Value, Stock Options Exercised	$3.89M+86.2%	$2.78M+67.5%	$1.14M—	$907K—	$2.09M—
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	——	$38.8M—	——	——	——
Vesting of early exercise stock options	——	——	——	——	$68K—
EBIT	-$174.06M-60.0%	-$155.6M-88.9%	-$141.12M-103%	-$121.07M-108%	-$108.8M—
EBITDA	-$173.93M-59.9%	-$155.5M-88.9%	-$141.04M-103%	-$121M—	-$108.74M—
EBITDA	-$173.93M-59.9%	-$155.5M-88.9%	-$141.04M-103%	-$121M—	-$108.74M—
EBIT	-$174.06M-60.0%	-$155.6M-88.9%	-$141.12M-103%	-$121.07M-108%	-$108.8M—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Bicara Therapeutics's income statement data come from?: Every line is extracted from Bicara Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.